Acadia Pharmaceuticals, Inc. (ACAD) Posts Q2 Loss of 10c/Share
Tweet Send to a FriendGet Alerts ACAD Hot Sheet
Price: $13.27 +2.00%
Revenue Growth %: -7.3%
Financial Fact:
Collaborative revenues: 417K
Today's EPS Names:
LBIX, ESEA, ISS, More
Revenue Growth %: -7.3%
Financial Fact:
Collaborative revenues: 417K
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade ACAD Now!
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q2 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $599 thousand versus the consensus estimate of $490 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- StreetInsider.com Pre-Open Movers 5/15: (MFLR) (CHCI) (SPWR) Higher; (XONE) (DE) (P) Lower (more...)
- Cisco Systems (CSCO) Tops Q3 EPS by 2c; Gross Margin Widens
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
